elranatamab
pfizer
['mmsm', 'elranatamab']
#eha2023 | poster | salomon manier, shares data on the safety and efficacy of elranatamab monotherapy in rrmm with prior bcma exposure. orr 46%, median pfs 5.5 mo, median os 12.1 mo, manageable toxicities, no new safety signals. #mmsm #myeloma 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma